RESEARCH
Built with clinicians.
Validated with institutions.
Our platform is being studied by leading academic medical centers across orthopedic and neurological rehabilitation. Below are active and pilot collaborations.
STUDY 01
IN PROGRESS
Adventist Healthcare
USA
PARKINSON'S DISEASE — VALIDITY & RELIABILITY
The validity and reliability of the Agado Live self-evaluation application for Parkinson's patients under various physical therapy evaluation tests in healthy adults. Objective: to determine the validity and reliability of the Agado Live self-evaluation for Parkinson's patients in healthy adults. Conclusion: the Agado app can be a valid, reliable, and feasible alternative to physical therapist manual measurement in evaluating PD patients across various environments and clinical settings.
STUDY 02
IN PROGRESS
Charité Universitätsmedizin Berlin
Berlin, Germany
PROGRESSIVE MULTIPLE SCLEROSIS
A pilot collaboration adapting Agado's AI-powered telerehabilitation platform for patients with progressive MS. The protocol delivers personalized, remotely supervised physiotherapy combined with cognitive elements — designed to slow disease progression and prepare for a future randomized controlled trial.
STUDY 03
IN PROGRESS
Sheba Medical Center
Tel HaShomer, Israel
POST-ACUTE ORTHOPEDIC REHABILITATION
A prospective 24-month cohort study examining the neuroprotective effects of a supervised aerobic exercise program delivered through the Agado platform in early-stage Parkinson's disease. The study tracks both clinical outcomes - motor function, cognition, and gait and molecular biomarkers including BDNF, irisin, and inflammatory markers, with the goal of establishing remotely delivered exercise as a measurable, non-pharmacological neuroprotective intervention for people living with PD.
MARKET CONTEXT
The shift to value-based and preventive care.
Health systems and payers are adopting reimbursement strategies that reward outcome-focused care. Physical therapy is now central to preventing chronic conditions and reducing the need for surgery or long-term medication.
$50.2B
U.S. PT market, 2024
55%
Private insurance share
Sources: Grand View Research, Mordor Intelligence, APTA Workforce Forecast 2022–2037.
Yet PT reimbursement on key CPT codes is down nearly 40% since 2002, while demand grows. The arithmetic only resolves with a fundamentally more efficient delivery model.
40%
Public insurance share
+11.87%
CAGR through 2031